ecancermedicalscience

Conference Report

Aspirin for the next generation

2 Apr 2013
Nick Henderson, Tom Smith

First used as an analgesic and antipyretic, investigations into aspirin’s anti-inflammatory effects led to its establishment in 1974 as a drug that altered the activity of platelets to influence the course and incidence of myocardial infarction and cerebrovascular disease. It became the standard in treatment and prevention of vascular disorders.

The 25th International Scientific Meeting on aspirin held at the Royal College of Physicians in London on 24th October 2012 took aspirin into fresh fields, among them cancer, diabetes, dementia and gynaecology.

Related Articles

Pavan Raju Kola, Amith Paruchuri, Nimisha Preman, Hemavathi Baskarane, Vishakha Hooda, Aparna Sharma, Ishaan Gupta, Saran Kumar, Shilpi Minocha, Pranay Tanwar, Mohit Kumar Divakar, Atul Batra
Pallavi Rajput, Vandita Pahwa, Charu Singh, Sankalp Sancheti, Ravikiran Pawar, Shikha Jain, Gurwinder Kaur, Kundan Rao, Navin Bansal, Rahat Brar, Tapas Dora, Ashish Gulia
Zakayo Ernesti, Emanuel Lugina, Chacha J Mwita, Felister Tupa, Herriethsiah S Noah, John R Ngowi, Charles Wood, Julius Mwaiselage, Salum J Lidenge
Sandro Casavilca-Zambrano, Juan Contreras-Mancilla, Camille Laurent, Jaqueline Montoya, Rosdali Diaz-Coronado, Jorge Honles, Ruddy Liendo-Picoaga, Jenny Bonifacio-Mundaca, Jhoysi Casas-Goñas, Juan Pablo Cerapio, Carlos Barrionuevo, Tatiana Vidaurre, Stéphane Bertani